Depressive symptom improver and composition containing the same
Lactobacillus gasseri, especially the OLL2809 strain, addresses the need for a side-effect-free treatment of depression by improving depressive symptoms and increasing Akkermancia bacteria through oral ingestion in pharmaceutical, quasi-drug, or food/beverage compositions.
Patent Information
- Application Number
- JP2024130227
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2019-05-31
- Filing Date
- 2024-08-06
- Publication Date
- 2024-11-06
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current antidepressant treatments for depression often have significant side effects, and there is a need for a gentler, side-effect-free alternative that can be continuously ingested, such as through food or beverages, to ameliorate depressive symptoms and increase beneficial intestinal bacteria like Akkermancia.
A depressive symptom improving agent containing Lactobacillus gasseri, particularly the OLL2809 strain, which is orally ingested to improve depressive symptoms and increase Akkermancia bacteria in the intestine, formulated into pharmaceutical, quasi-drug, or food/beverage compositions.
The Lactobacillus gasseri-based agent effectively reduces depressive symptoms and increases Akkermancia bacteria, providing a gentle, side-effect-free treatment option for depressive symptoms and improving intestinal flora.
Smart Images

Figure 2024156916000001 
Figure 2024156916000002 
Figure 2024156916000003
Abstract
Description
[Technical field]
[0001] The present invention relates to an agent for improving depressive symptoms, and a pharmaceutical composition, a quasi-drug composition, or a food and drink composition containing the same. The present invention also relates to a composition for increasing Akkermancia bacteria present in the intestine. [Background technology]
[0002] Depression is a mood disorder (depressive disorder) in which emotions are suppressed for some reason, and the person loses the energy to live a social life and has difficulty adapting to society. Depression symptoms (depressive symptoms) are diverse, and include mental symptoms such as depressed mood, sadness, loss or decline in motivation, interest, and joy, self-blame and guilt, loss or decline in self-esteem, inhibition of thought, impatience, decreased concentration, and suicidal ideation (repeated thoughts of death or suicide), and physical symptoms such as decreased appetite (weight loss), insomnia (difficulty falling asleep, difficulty in deep sleep, early morning awakening), fatigue, easy fatigue, decreased libido, headache, heavy head, dizziness, and diarrhea and constipation. The number of people who are considered to be depressed or at risk of depression is steadily increasing, and in recent years, it has been reported that one in 15 people may suffer from depression at least once in their lifetime (Non-Patent Document 1).
[0003] One of the methods for treating depression is pharmacotherapy using antidepressants. Tricyclic or tetracyclic antidepressants are widely used as antidepressants, but they are known to have strong side effects such as low blood pressure, drowsiness, dry mouth, constipation, forgetfulness, gastrointestinal disorders, and headaches. For this reason, selective serotonin reuptake inhibitors (SSRIs) and serotonin-noradrenaline reuptake inhibitors (SNRIs), which have fewer side effects, are often used in recent years. However, these drugs are known to cause strong nausea when first taken, and to cause headaches, dizziness, and general fatigue if suddenly stopped or forgotten to take them. For this reason, there is a demand for a treatment method that is gentle on the body and has few or no side effects.
[0004] Incidentally, Lactobacillus gasseri, a type of Lactobacillus lactic acid bacteria, has been known to have an effect of reducing psychological stress such as anxiety and tension (stress-reducing effect) (Patent Document 1). It is also known that the fermentation product of Lactobacillus pentosus, another type of Lactobacillus lactic acid bacteria, has an anti-stress effect (Patent Document 2). There are various causes of stress, such as mental tension, mental instability during menopause, and anxiety and tension about the future, and excessive stress leads to undesirable physical and mental symptoms such as irritability, social anxiety disorder, mental fatigue, and sleep disorders.
[0005] When the body is subjected to such stress, serotonin, a type of monoamine in the brain, is released, and the amount of serotonin in the brain decreases. This state continues for a certain period of time even after the stress is released, and the brain becomes deficient in serotonin, causing various symptoms such as lethargy, laziness, depressed mood, sleep disorder, chronic fatigue, loss of appetite, migraine, and hypersensitivity (Patent Document 3). These depressive symptoms observed after stress loading also support the theory that depression is related to a decrease in serotonin function in the brain (Non-Patent Document 2). The above Patent Document 3 describes that Lactobacillus casei, a lactic acid bacterium of the Lactobacillus genus, has the effect of improving serotonin deficiency after stress is released. However, it is not clear whether Lactobacillus gasseri, which is known to have a stress-reducing effect, has an effect of affecting depressive symptoms that occur after stress loading. [Prior art documents] [Patent documents]
[0006] [Patent Document 1] International Publication No. 2014 / 132982 [Patent Document 2] JP 2010-155790 A [Patent Document 3] International Publication No. 2017 / 047777 [Non-patent literature]
[0007] [Non-Patent Document 1] Sakamoto, Y., Ogawa, T., Ogawa, M., Matsuo, Y., Hashikawa, N., Hashikawa, N.. Effects of 15 days of stress on behavior and hippocampal neurons in ICR mice. Yakugaku Zasshi. 2015, Vol. 135, No. 1, p. 151-158. [Non-Patent Document 2] Soichi Nomura; Special Edition Japanese Clinical Psychiatric Syndrome I 38:236-239, 2003 [Non-Patent Document 3] Collad MCet al, Intestinal integrity and Akkermansia muciniphila, a mucin-degrading member of the intestinal microbiota present in infants, adults, and the elderly. Appl. Environ. Microbiol. 73, 7767-7770 (2007). [Non-Patent Document 4] Everard A, et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc. Natl. Acad. Sci. USA. 110: 9066-9071 (2013). Summary of the Invention [Problem to be solved by the invention]
[0008] As described above, the object of the present invention is to provide an agent for improving depressive symptoms that has no or few side effects and is gentle on the body. More preferably, the object of the present invention is to provide an agent for improving depressive symptoms that can be suitably used to prepare food and drink for improving depressive symptoms that can be continuously ingested, and a pharmaceutical composition, a quasi-drug composition, and a food and drink composition for improving depressive symptoms that contain the agent for improving depressive symptoms. The present invention also provides a composition for increasing Akkermancia bacteria present in the intestine. The objective is to [Means for solving the problem]
[0009] The present inventors have been conducting intensive research to solve the above problems, and have found that oral ingestion of Lactobacillus gasseri has the effect of improving depressive symptoms in addition to the above-mentioned stress-reducing effect, and also has the effect of acting on the intestinal flora to increase the bacteria belonging to Akkermancia, a type of beneficial bacteria present in the intestine. The invention has been completed.
[0010] The present invention has the following embodiments. (I) Drugs for improving depressive symptoms (I-1) An agent for improving depressive symptoms, the agent comprising Lactobacillus gasseri cells, a processed product thereof, or a fermented product containing these as an active ingredient. The depressive symptoms include those that occur after being released from stress (hereinafter the same). (I-2) An agent for improving depressive symptoms according to (I-1), wherein the Lactobacillus gasseri is Lactobacillus gasseri OLL2809 strain deposited under accession number NITE BP-72.
[0011] (II) Composition for improving depressive symptoms (II-1) A composition for improving depressive symptoms, comprising an effective amount of the agent for improving depressive symptoms according to (I-1) or (I-2). (II-2) The composition according to (II-1), which is a pharmaceutical composition, a quasi-drug composition, or a food and drink composition.
[0012] (III) Method for using Lactobacillus gasseri cells (III-1) A step of preparing a pharmaceutical composition, a quasi-drug composition, or a food and drink composition by blending Lactobacillus gasseri cells or a processed product thereof, or a fermented product containing these A method for using Lactobacillus gasseri cells or a processed product thereof, or a fermented product containing either, for imparting an effect of improving depressive symptoms to a pharmaceutical composition, a quasi-drug composition, or a food and drink composition, the method comprising the steps of: (III-2) The method of use according to (III-1), wherein the Lactobacillus gasseri is Lactobacillus gasseri OLL2809 strain deposited under the accession number NITE BP-72.
[0013] (IV) Use of Lactobacillus gasseri cells, etc. (IV-1) Use of Lactobacillus gasseri cells or a processed product thereof, or a fermented product containing either of them, for producing an agent for improving depressive symptoms, or a pharmaceutical composition, a quasi-drug composition, or a food and beverage composition containing the same. (IV-2) The use according to (IV-1), wherein the Lactobacillus gasseri is Lactobacillus gasseri OLL2809 strain deposited under the accession number NITE BP-72.
[0014] (V) Methods for improving depressive symptoms (V-1) A method for improving depressive symptoms in a human or non-human mammal, comprising the step of administering to said human or non-human mammal a composition containing as an active ingredient Lactobacillus gasseri cells or a processed product thereof, or a fermented product containing these. (V-2) The method described in (V-1), wherein the Lactobacillus gasseri is Lactobacillus gasseri OLL2809 strain deposited under accession number NITE BP-72.
[0015] (VI) Composition for increasing intestinal Akkermancia bacteria (VI-1) A composition for increasing intestinal Akkermancia bacteria, comprising as an active ingredient Lactobacillus gasseri cells or a processed product thereof, or a fermented product containing these. (VI-2) The composition for increasing intestinal Akkermancia bacteria according to (VI-1), wherein the Akkermancia genus is Akkermancia muciniphila. (VI-3) A composition for increasing intestinal Akkermancia bacteria according to (VI-1) or (VI-2), wherein the Lactobacillus gasseri is Lactobacillus gasseri OLL2809 strain deposited under accession number NITE BP-72. (VI-4) A method for producing a composition for increasing intestinal Akkermancia bacteria by using Lactobacillus subtilis Use of Lactobacillus gasseri cells or a processed product thereof, or a fermented product containing these. (VI-5) A method for increasing Akkermancia bacteria in the intestines of humans or non-human mammals, comprising the step of administering to humans or non-human mammals a composition containing Lactobacillus gasseri cells, a processed product thereof, or a fermented product containing these as an active ingredient. The method involves modifying the intestinal flora of humans or non-human mammals to increase the abundance of Akkermancia bacteria. It can also be said to be a method of transforming Effect of the Invention
[0016] According to the depressive symptom improving agent of the present invention, by adding it during the production of a pharmaceutical composition, a quasi-drug composition, or a food and drink composition, it is possible to impart a depressive symptom improving effect to the pharmaceutical composition, a quasi-drug composition, or a food and drink composition. In other words, according to the depressive symptom improving agent of the present invention, a pharmaceutical composition, a quasi-drug composition, or a food and drink composition that exerts a depressive symptom improving effect can be produced and provided. By using the composition for improving depressive symptoms (pharmaceutical composition, quasi-drug composition, or food and drink composition) of the present invention thus produced, it is possible to improve and treat depressive symptoms in humans or non-human mammals. [Brief description of the drawings]
[0017] [Figure 1] The following shows the results of the (1) forced swimming test conducted in Experimental Example 1. In the figure, "*" indicates a significant difference of p<0.05 compared to the non-stressed group (control group), and "#" indicates a significant difference of p<0.05 compared to the stressed group (vehicle group) (t-test). [Diagram 2] The figures show the results of the (2) sucrose preference test conducted in Experimental Example 1. In the figure, "*" indicates a significant difference of p<0.05 compared to the non-stressed group (control group) (t-test). [Diagram 3] 1 shows the results of the forced swimming test carried out in Experimental Example 2. In the figure, "*" indicates a significant difference of p<0.05 compared to the non-stressed group (control group). [Figure 4] This shows the results of an analysis of the number of bacteria (Akkermancia muciniphila) in feces performed in Experimental Example 2. In the figure, "*" indicates a significant difference of p<0.05 compared to the non-stressed group (control group), and "#" indicates a significant difference of p<0.05 compared to the stressed group (vehicle group) (t-test). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0018] (I) Drugs for improving depressive symptoms The depressive symptom improving agent that is the subject of the present invention is characterized by containing Lactobacillus gasseri cells as a lactic acid bacterium as an active ingredient.
[0019] As long as it exerts the effect of the present invention (effect of improving depressive symptoms), any Lactobacillus gasseri may be used. Preferably, it is Lactobacillus gasseri OLL2809 (hereinafter, simply referred to as "OLL2809 strain") isolated from adult human feces. The strain in question has been identified as "Lactobacillus gasseri OLL2809" and is available for purchase from 20 On February 1, 2005 (the date of original deposit), it was deposited at the Patent Microorganisms Depositary Center of the National Institute of Technology and Evaluation (2-5-8 Kazusa Kamatari, Kisarazu City, Chiba Prefecture, Japan) under the accession number "NITE P-72". On January 18, 2006, it was transferred from the original deposit to an international deposit under the Budapest Treaty and is deposited under the accession number "NITE BP-72".
[0020] Lactobacillus gasseri, specifically the OLL2809 strain, is a gram-positive rod-shaped bacterium. The colonies on MRS Agar (Difco) are round, pale yellow, and flat. The bacterium exhibits homolactic fermentation, is capable of growing at 45°C, and is capable of fermenting glucose, mannose, fructose, galactose, sucrose, cellobiose, lactose and trehalose.
[0021] The medium for culturing Lactobacillus gasseri, especially the OLL2809 strain, is Any medium that is normally used for culture may be used without any particular limitation. That is, any medium that contains a suitable amount of a nitrogen source, inorganic substances and other nutrients in addition to a main carbon source may be used. As the carbon source, lactose, glucose, sucrose, fructose, starch hydrolysate, blackstrap molasses, etc. may be used depending on the assimilation ability of the bacteria. As the nitrogen source, organic nitrogen-containing substances such as casein hydrolysate, whey protein hydrolysate, soy protein hydrolysate, etc. may be used. In addition, meat extract, fish extract, yeast extract, etc. may be used as a growth promoter, if necessary.
[0022] The culture is preferably performed under anaerobic conditions, but may be performed under microaerobic conditions using liquid static culture or the like that is commonly used. For anaerobic culture, known techniques such as a method of culturing under a carbon dioxide gas layer can be applied, but other methods may also be used. The culture temperature is generally preferably about 30 to 40°C, but other temperature conditions may be used as long as the bacteria can grow at that temperature. The medium during culture is preferably maintained in the pH range of 6 to 7, but other pH conditions may be used as long as the bacteria can grow at that pH. Culture may also be performed under batch culture conditions. The culture time is usually preferably 10 to 24 hours, but other culture times may be used as long as the bacteria can grow.
[0023] As long as the effects of the present invention are achieved, Lactobacillus gasseri cells may be used in the form of either live or dead cells. It does not matter. It is preferably a live cell. In addition, as long as the effect of the present invention is achieved, it does not matter whether the cell is wet or dry. In addition, the depressive symptom improving agent of the present invention contains Lactobacillus gasseri cells, and as long as the effect of the present invention is achieved, it is not limited to those containing the cells in an isolated and purified state, and may be a processed product thereof, or a product fermented using the cells or the processed product thereof (fermented product). Here, the "processed product" is not limited, but examples thereof include Lactobacillus gasseri cultures and various processed products thereof (for example, fractionated products such as culture supernatant and culture pellets; heat-treated products; sterilized products; crushed products; concentrated and diluted products; dried products such as spray drying, freeze drying and vacuum drying; and products obtained by combining various processes, etc.). Furthermore, examples of "fermented products" include, but are not limited to, products obtained by fermenting edible animal ingredients (e.g., milk, seafood, meat, or processed products thereof) or edible plant ingredients (soybeans, vegetables, or processed products thereof) using Lactobacillus gasseri cells.
[0024] In addition, in order to improve palatability, in addition to the active ingredient Lactobacillus gasseri, preferably the OLL2809 strain, the fermented product may be prepared with a purpose other than the effect of the present invention, such as improving palatability. However, it is also possible to use other microorganisms in combination. Examples of such microorganisms include, but are not limited to, Lactobacillus bacteria other than Lactobacillus gasseri, Bifidobacterium bacteria, Streptococcus bacteria, Lactococcus bacteria, Enterococcus bacteria, Bacillus bacteria, yeasts belonging to the Saccharomyces or Candida genera, etc. However, the depressive symptom improving agent of the present invention does not contain lactic acid bacteria or yeasts other than Lactobacillus gasseri, and contains only Lactobacillus gasseri, preferably only the OLL2809 strain, and the bacterial cells, processing thereof, etc. It is preferable that the present invention includes natural products and fermented products thereof.
[0025] The depressive symptom improving agent of the present invention is used to impart a depressive symptom improving effect to a pharmaceutical composition, a quasi-drug composition, or a food and drink composition (including a feed composition; the same applies below) for humans or non-human mammals. In particular, it is used to manufacture a pharmaceutical, a quasi-drug, or a food and drink composition used to improve depressive symptoms in humans or non-human mammals. Here, non-human mammals include non-human primates, rodents (e.g., mice, rats, rabbits, guinea pigs, etc.), dogs, cats, etc. These non-human mammals include laboratory animals in which symptoms mimicking depressive symptoms have been artificially developed, such as the social defeat stress mouse described below. Thus, the depressive symptom improving agent of the present invention can be used as a raw material for manufacturing a pharmaceutical composition, a quasi-drug composition, or a food and drink composition, particularly a composition for improving depressive symptoms described below. The amount of the agent for improving depressive symptoms of the present invention in a pharmaceutical composition, quasi-drug composition, or food and beverage composition varies depending on the form (dosage form) of the composition, the subject (human or non-human mammal, gender, etc.) and their symptoms, and is not particularly limited, but can be appropriately selected and set within the range of 0.001 to 100 mass%. Therefore, the amount of Lactobacillus gasseri cells contained in the agent for improving depressive symptoms of the present invention can be set so that the finally prepared pharmaceutical composition, quasi-drug composition, or food and beverage composition exerts the effects of the present invention, and is not limited to, but can be selected from the range of 1 x 10 6 It is preferable to set the number of particles per gram or more.
[0026] The form of the depressive symptom improving agent of the present invention is not particularly limited, and may be any form that can be added to a pharmaceutical composition, a quasi-drug composition, or a food and drink composition during production. It may be a culture or processed product of Lactobacillus gasseri cells, or it may be prepared into various formulation forms (e.g., tablets, pills, powders, granules, capsules, suspensions, etc.) by adding any carrier or additive thereto.
[0027] The "depressive symptoms" of the present invention are those in humans or non-human mammals that are mimicked in a social defeat stress model mouse (Kudryavtseva NN, et al., Pharmacol. Biochem. Behav., 38, 315-320 (1991)), which is an animal model of depression. The depression symptoms are depressive symptoms that occur in the body, and are mood disorders or dysthymia including any of the following symptoms: social avoidance (social withdrawal), lethargy (reduced energy), anhedonia, loss of interest, decreased concentration, decreased or increased appetite, abnormal sleep rhythm, increased fatigue or tiredness, etc. Preferably, the depression symptoms are lethargy or anhedonia. Various subtypes of depression, symptoms of each type, and diagnostic methods thereof are described in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM IV), which can be referred to. The depressive symptoms include depressive symptoms that occur after being released from stress load.
[0028] The social defeat stress model is prepared by placing a test animal (intruder animal) in the same cage as an aggressive animal (resident animal) and subjecting the test animal to social stress such as mental tension, anxiety, and fear. In particular, animals sensitive to stress such as mice and rats show social avoidance, lethargy (reduced vitality), and / or anhedonia reaction even after being released from the stress load, and show behavioral changes similar to human depression in behavioral tests. Examples of behavioral tests include the forced swim test (e.g., Porsolt et al., Nature 266,730 (1977); and Petit-Demouliere et al., Psychopharmacology, 177, 245 (2005)), and the sucrose preference test (e.g., Kurre Nielson, et al., Behavioural Brain Research 107, 21-33, (2000)), as shown in the experimental examples described below. These tests are widely used to screen antidepressants.
[0029] [Forced swimming test] Social defeat stress model animals are placed in a cylindrical container filled with water to a depth where the tail cannot reach the bottom, and swimming time and immobility time are measured during the test period. In animals in a depressed state, immobility time is prolonged, and administration of antidepressants reduces immobility time. This test allows us to measure the aforementioned depressive symptoms, particularly lethargy (reduced vitality). [Sucrose preference test] A bottle containing sucrose water and a bottle containing drinking water are given to a social defeat stress model animal at the same time, and the percentage of animals that drink the sucrose water is calculated as sucrose preference. Normal animals that are not depressed prefer to drink the sucrose water, but the percentage of animals that drink the sucrose water decreases in depressed animals, and the sucrose preference is restored when an antidepressant is administered. This test can be used to measure the aforementioned depressive symptoms, particularly anhedonia.
[0030] The term "improvement" in the present invention includes temporary, intermittent or sustained relief, alleviation, decrease or elimination of depressive symptoms occurring in humans or non-human mammals. It preferably includes recovery to a normal state or a state close to the normal state without depressive symptoms. Therefore, a pharmaceutical composition or quasi-drug composition prepared using the depressive symptom improving agent of the present invention can be used to treat depressive symptoms in patients with depression. In addition, a food and drink composition (including a feed composition) prepared using the depressive symptom improving agent of the present invention can be used to alleviate, alleviate, decrease or elimination of the symptoms in humans or non-human mammals having depressive symptoms.
[0031] (II) Composition for improving depressive symptoms The composition for improving depressive symptoms that is the subject of the present invention (hereinafter also referred to as "the composition for improving depressive symptoms") contains the above-mentioned agent for improving depressive symptoms of the present invention (hereinafter also referred to as "the agent for improving depressive symptoms") and can be prepared using the agent for improving depressive symptoms. That is, the composition for improving depressive symptoms contains Lactobacillus gasseri cells or a processed product thereof, or a fermented product containing these as an active ingredient. The composition for improving depressive symptoms includes pharmaceutical compositions, quasi-drug compositions, and food and drink compositions. Furthermore, the food and drink compositions include feed compositions as food and drink when the target is a non-human mammal, unless otherwise specified.
[0032] The ratio of the depressive symptom improving agent contained in the composition for improving depressive symptoms of the present invention is not particularly limited as long as the composition for improving depressive symptoms contains an effective amount of Lactobacillus gasseri cells that exhibits the effects of the present invention. Specifically, although it varies depending on the use, form, and symptoms of the subject of the composition for improving depressive symptoms, when the composition for improving depressive symptoms is a pharmaceutical composition or a quasi-drug composition, the ratio is 1×10 per day intake. 6 10 or more, preferably 1×10 7 10 or more, more preferably 1×10 8 10 or more, particularly preferably 1×10 9The composition can be adjusted to contain 1×10 Lactobacillus gasseri cells or more. In the case of a food or drink composition, the composition can be adjusted to contain 1×10 Lactobacillus gasseri cells per day for humans. 6 10 or more, preferably 1×10 7 10 or more, more preferably 1×10 8 10 or more, particularly preferably 1×10 9 or more per day, and 1×10 per day for non-human mammals 6 Each setting can be adjusted to include one or more Lactobacillus gasseri organisms.
[0033] The composition for improving depressive symptoms can be prepared in the conventional form for each product as a drug, quasi-drug, or food or drink, depending on the application and administration method, preferably as a food or drink.
[0034] When the composition for improving depressive symptoms is prepared as a pharmaceutical or quasi-drug, its form may be, for example, a tablet, a pill, a capsule, a granule, a powder, a powder, a liquid, a syrup, a suspension, an emulsion, a suppository, or an injection. It is preferably an oral administration form. These various preparations can be prepared according to a conventional method using known auxiliary agents that can be normally used in the field of pharmaceuticals and quasi-drugs, such as excipients, binders, disintegrants, lubricants, solubilizing agents, suspending agents, coating agents, fillers, bulking agents, moisturizing agents, surfactants, and pH adjusters, in addition to the main agent, the composition for improving depressive symptoms. In addition, various additives such as preservatives, antioxidants, colorants, flavorings, flavorings, sweeteners, and odorants can also be blended. The preparation method can be performed by a method well known in the art. The pharmaceutical composition or quasi-drug composition of the present invention prepared using the composition for improving depressive symptoms can be administered to a patient with depression, and can be used for the treatment of the patient with depression, such as improving the depressive symptoms of the patient with depression. For patients suffering from depression, a pharmaceutical composition or quasi-drug composition containing an effective amount of Lactobacillus gasseri cells described above can be administered once a day or in divided doses about two to three times a day.
[0035] When the composition for improving depressive symptoms is prepared as a food or drink, the form of the food or drink can be the various preparation forms described above, as well as the general processed food or drink form. Examples of processed food or drink include, without limitation, dairy processed foods such as fermented milk, lactic acid bacteria drinks, dairy drinks, yogurt, cheese, and powdered milk (skim milk powder, modified milk powder, milk powder for lactating women, fat milk powder, etc.); beverages (non-alcoholic beverages, alcoholic beverages); vegetable processed foods; fruit processed foods; oil and fat processed foods; seafood processed foods; meat processed foods; luxury foods; seasonings; confectionery (Western confectionery, Japanese confectionery, chocolate, frozen desserts, iced desserts, fresh confectionery, baked confectionery, candy, gummy, jelly, tablet confectionery, etc.); frozen foods; retort foods; canned foods; bottled foods; instant foods; liquid foods, etc. These foods and drinks include, for example, specific health foods and functional foods that claim to reduce, alleviate, or lower depressive symptoms, as well as functional foods such as nutritional composition-labeled foods, foods for sick people, and foods for special dietary uses.
[0036] The manufacturing method of these foods and beverages can be performed by a method well known in the art. For example, in the case of yogurt, Lactobacillus gasseri (preferably OLL2809 strain) is used. Yogurt can be produced through a process of preparing a starter using the starter, a process of adding the starter to pretreated milk and culturing it, a cooling process, a flavoring process, a filling process, etc. For cheese, for example, a process of adding Lactobacillus gasseri (preferably the OLL2809 strain) as a starter to milk that has been pretreated such as pasteurized and then fermenting it with lactic acid, a process of adding rennet to make cheese, etc. The dairy products can be produced through a process of forming a milk curd, a curd cutting process, a whey draining process, a salting process, a maturation process, etc. Alternatively, in the production of the various dairy products, other lactic acid bacteria can be used as a starter, and Lactobacillus gasseri (preferably OLL2809 strain) can be added during the production process. Or a processed product thereof may be added. The food and drink composition of the present invention thus prepared can be ingested by a human or non-human mammal having a depressive symptom to alleviate, reduce, lower or eliminate the depressive symptom. A food and drink composition containing the above-mentioned effective amount of Lactobacillus gasseri cells can be ingested by a human or non-human mammal once a day or in divided portions about 2 to 3 times a day.
[0037] Regarding the composition for improving depressive symptoms, the definitions of depressive symptoms, improvement, Lactobacillus gasseri, OLL2809 strain, bacteria, processed products, fermented products, etc. and the preparation methods thereof are described in the above section (I). and the same applies to this section as well.
[0038] (III) Composition for increasing intestinal Akkermancia bacteria As shown in Experimental Example 2, when the aforementioned Lactobacillus gasseri cells or a processed product thereof, or a fermented product containing them, are orally ingested, they act on the intestinal flora to promote the proliferation of Akkermancia bacteria present in the intestine, thereby exerting the effect of increasing Akkermancia bacteria in the intestine (see Experimental Example 2). For this reason, Lactobacillus gasseri cells or a processed product thereof, or a fermented product containing them can be used as a composition for increasing Akkermancia bacteria in the intestine. It can be suitably used.
[0039] The Lactobacillus gasseri cells or processed products thereof, or fermented products containing them, used herein are as described in (I) above, and the descriptions therein can be incorporated herein by reference. In addition, the composition for increasing intestinal Akkermancia bacteria, which is the subject of the present invention, is orally ingested. The composition is preferably a food or drink composition (including a feed composition). The form (including the dosage form), the amount of Lactobacillus gasseri cells to be blended in the composition, and the number of administrations (ingestions) can be determined by referring to the descriptions in (I) and (II) above.
[0040] Bacteria belonging to the Akkermancia species include enterobacteria present in the intestines of humans and non-human mammals. There are no particular limitations as long as the bacterium is used. A preferred bacterium is Akkermancia muciniphila. A. muciniphila is a gram-positive bacterium capable of assimilating mucin. It has been reported that this bacterium has an anti-inflammatory effect and blood glucose level improving effect via the intestinal mucosal barrier improving effect (Non-Patent Document 4), and it is an intestinal bacterium that has attracted attention, including the development of it as a pharmaceutical product. For this reason, the composition for increasing intestinal Akkermancia bacteria of the present invention can be orally ingested to increase the intestinal Akkermancia bacteria. It is expected that this will improve the bacterial flora, and thus improve the intestinal mucosal barrier, and thus provide various health functional effects.
[0041] As described above, in this specification, the terms "comprise" and "contain" include the meanings of "consisting of" and "consisting essentially of". EXAMPLES
[0042] In the following, the present invention will be described using experimental examples to aid in understanding the configuration and effects of the present invention. However, the present invention is not limited by these experimental examples. Unless otherwise specified, the following experiments were performed at room temperature (23±5°C) and atmospheric pressure. In addition, the animals used in the following experiments, as well as the experiments and care of the animals, were approved by the Animal Experiment Management Committee of Okayama University of Science and were performed under conditions in accordance with the guidelines stipulated by the university, which comply with domestic and international laws and policies.
[0043] Experimental example 1 Improvement of depressive symptoms 1. Preparation of Lactobacillus gasseri OLL2809 Lactobacilli gasseri OLL2809 was stimulated and cultured twice in Lactobacilli MRS Broth (Difco) (37°C, 18 hours). The stimulated culture was inoculated into the same medium at 1% and cultured at 37°C for 18 hours. After harvesting, the bacteria were washed once with sterile distilled water.
[0044] 2. Preparation of Social Defeat Stress Model Animals Eight-week-old male C57BL / 6J mice (average body weight 23.3±0.47 g) were divided into two groups: a non-stressed group (control group) (non-STRESS: n=13 mice) and a stressed group (STRESS: n=18 mice). The stressed group (stressed mice) was maintained for 4 weeks (Day 1 to Day 29). ), and male ICR mice (resident mice) of about 30 weeks of age, which are larger and more aggressive than the mice in question, were fed daily. Mice) were kept in the same cage for 10 minutes per day and exposed to fear and defeat stress. Specifically, one resident mouse was placed in one cage, and one stressed mouse was placed in the cage. The mice were placed in a cage and allowed to face each other for 10 minutes. After that, the cage was divided by a transparent partition with holes, and the mice were allowed to stay there for 24 hours. The next day, the stressed mice were placed in a cage with one other resident mouse, and the mice were subjected to the same stress. All stress-loaded groups were maintained under controlled environmental conditions (23±2°C, 60% relative humidity, 12-hour light / dark cycle [lights on at 7am, lights off at 7pm], food and water available ad libitum).
[0045] 3. Behavioral Testing On the day after the last day of stress loading (Day 30), a forced swimming test was performed. After that, the stressed groups were divided into two groups, a normal diet group (vehicle group) and a Lactobacillus gasseri OLL2809 intake group (OLL2809 group), and were reared under the same controlled environmental conditions as above for 2 weeks (Day 30 to Day 44). The L. gasseri OLL2809 intake group (OLL2809 group) was administered 3.5 g of powdered AIN-93M (manufactured by CLEA Japan, Inc.) with 1.75 mL of water and L. gasseri OLL2809 (2 x 10 9 cfu) and made into balls. The rats were given one ball of AIN-93M powder per day. The rats in the vehicle group were given one ball of AIN-93M powder per day, which was made by mixing 3.5 g of powder with 1.75 mL of water. After two weeks of feeding, on Day 45, a forced swimming test was conducted as a behavioral test. In addition, a sucrose preference test was conducted for four days from Day 45 to Day 48.
[0046] (1) Forced swimming test 800 mL of water adjusted to 28°C in a thermostatic bath was placed in a 1 L glass cylindrical beaker (height 15 cm, diameter 11.5 cm), and mice (non-stressed group [control group] (n=9), Stressed mice (vehicle group (n=9), OLL2809 group (n=9)]) were immersed for 6 minutes and forced to swim. The behavior of the mice was observed for 5 minutes from 1 minute after immersion, and the time the mice remained floating on the water surface without struggling (including the time when the mice made small movements to get their head out of the water) was recorded as immobility time (seconds).
[0047] (2) Sucrose preference test Two water bottles were prepared, one containing water and the other containing a 2% by mass sucrose solution, and mice (control group (n=4), vehicle group (n=9), OLL2809 group (n=9)) were allowed to freely consume water for 2 days from Day 45 to Day 46 (habituation learning). On the second day, the two water bottles were switched and the mice were allowed to freely consume water for 2 days (Day 47 to Day 48), and the amount of water consumed by each of the water and sucrose solution was measured every 4 hours. The value of "(sucrose solution intake / total water intake) x 100" (%) was calculated from the average of the total amount of water consumed and the amount of sucrose solution consumed over 4 hours over the two days, and this was used to evaluate sucrose preference.
[0048] 4. Test Results The results of the forced swimming test are shown in Figure 1, and the results of the sucrose preference test are shown in Figure 2. As shown in Figure 1, in the forced swimming test, the immobility time (seconds) was significantly increased in the stressed group (stressed group [vehicle group]) compared to the non-stressed group (non-stressed group [control group]). In contrast, the immobility time was significantly decreased by feeding L. gasseri OLL2809 (OLL2809 group). Although we are not bound to the reason (cause), it is believed that the stress group experienced depressive symptoms (lethargy, decreased vitality, easy fatigue) and had a significant increase in immobility time, but that the intake of L. gasseri OLL2809 improved (alleviated, mitigated, decreased) the depressive symptoms.
[0049] As shown in Figure 2, in the sucrose preference test, the amount of sucrose intake was significantly decreased by stress (vehicle group), whereas the amount of sucrose intake was significantly decreased by L. gasseri OLL2809 (vehicle group). It was found that the sucrose intake of the stressed group (OLL2809 group) increased significantly to the same level as that of the non-stressed group (control group). Although we are not bound to the reason (cause), it is thought that the stressed group developed depressive symptoms (loss of interest and pleasure) and disliked sucrose intake, but that the depressive symptoms were improved (alleviated, mitigated, decreased) by taking L. gasseri OLL2809. From the above results, it is recognized that L. gasseri OLL2809 has the effect of improving depressive symptoms.
[0050] Experimental Example 2: Effects on intestinal flora While stress load changes the gut flora via the nervous system, endocrine system, or immune system, it is becoming clear that the gut flora also affects the host's stress response via these signaling pathways. Therefore, the effects of stress on the gut flora, particularly the effects of Lactobacillus gasseri administration on the gut flora, were evaluated by creating social defeat model mice in the same manner as in Experimental Example 1 and conducting a forced swimming test.
[0051] 1. Test Method A social defeat model mouse (stressed group) was prepared in the same manner as described in Experimental Example 1. Specifically, 8-week-old male C57BL / 6J mice were divided into a non-stressed group (control group, n = 7) and stress group (OLL2809 group [n = 5], vehicle group [n = 5]). The stressed mice were exposed to social defeat stress every day for 4 weeks, and the OLL2809 mice were then injected with L. gasseri OLL2809 (2 x 10 9 cfu) into dumplings The rats in the vehicle group were fed food containing only water in the dumplings. After feeding each diet every day for 2 weeks, feces were collected from each group of mice before the forced swimming test. 20 mg of feces was weighed into EasyBeads (AMR). The feces were crushed using FastPrep (MP-Biomedicals) and analyzed using the RSC PureFood GMO and Authentication Kit (Promega). ) and an automated nucleic acid extractor (Maxwell, Promega) were used to extract DNA. The number of Akkermancia muciniphila bacteria was quantified by real-time PCR using the extracted DNA.
[0052] Real-time PCR was performed with reference to the method of Collado et al. (Non-Patent Document 3). The composition was 10 μL of PowerUP SYBR Green Master Mix (Applied Biosystems), 4 μL of diluted extracted DNA, and 0.18 μL of forward and reverse primers adjusted to 100 pmol / μL. The PCR reaction conditions were: 20 μL at 50°C for 2 h. After heating at 95°C for 2 min, denaturation was performed at 95°C for 15 s and annealing / extension reaction at 60°C for 1 min was repeated 40 times. PCR reactions were carried out using a QuantStudio 3 real-time PCR system (Applied biosystems). The forward and reverse primers used had the following sequences: AM1: 5'CAG CAC GTG AAG GTG GGG AC (SEQ ID NO: 1); AM2: 5' CCT TGC GGT TGG CTT CTT CAG AT (SEQ ID NO: 2).
[0053] Akkermancia muciniphila ATCC BAA-835 obtained from ATCC (American Type Culture Collection) was used to create the standard curve. The strain was cultured according to a prescribed method, and 10 11 DNA was extracted from cfu in the same manner as above, and 10 5 ~10 9 A standard curve was made over a range of cfu. The analysis was performed using the ΔΔCt method.
[0054] 2. Test Results (1) Forced swimming test The results of the forced swimming test are shown in Figure 3. As in Experiment 1, the immobility time (seconds) was On the other hand, because the n-number was small, no significant decrease was observed in the OLL2809 group compared to the vehicle group, but a significant increase was observed compared to the control group. As in Experimental Example 1, it was observed that oral intake of Lactobacillus gasseri had the effect of improving (relieving, alleviating, or reducing) depressive symptoms.
[0055] (2) Number of Akkermancia muciniphila bacteria in feces The results of the analysis of fecal A. muciniphila bacterial count are shown in Figure 4. As shown in Figure 4, no change was observed in the fecal A. muciniphila bacterial count in the vehicle group compared to the control group. On the other hand, a significant increase was observed in the OLL2809 group compared to the vehicle and control groups. A. muciniphila has been reported to have an anti-inflammatory effect via the improvement of the intestinal mucosal barrier, and in turn an effect of improving blood glucose levels. Since OLL2809 is a well-known intestinal bacterium, oral intake of OLL2809 may improve the intestinal mucosal barrier. It is expected that this will have a beneficial effect on the body, or that various health functional effects will be achieved through this effect. [Sequence List Free Text]
[0056] SEQ ID NOs: 1 and 2 show the nucleotide sequences of the forward and reverse primers for PCR used to quantify the number of Akkermancia muciniphila bacteria.
Claims
1. A composition for increasing Akkermancia bacteria, comprising, as an active ingredient, Lactobacillus gasseri cells or a processed product thereof, or a fermented product containing either of them.
2. The composition for increasing Akkermancia bacteria according to claim 1, wherein the Akkermancia bacteria is Akkermancia muciniphila.
3. 3. A composition for increasing Akkermansia bacteria according to claim 1 or 2, wherein the Lactobacillus gasseri is Lactobacillus gasseri OLL2809 strain deposited under accession number NITE BP-72.
4. A composition for increasing Akkermansia genus bacteria, as described in either claim 1 or 2, which is an oral composition for imparting to humans or non-human mammals at least one effect selected from an intestinal mucosal barrier improving effect, an anti-inflammatory effect, and a blood glucose level improving effect.
5. The composition for increasing Akkermansia bacteria according to any one of claims 1 to 4, which is a pharmaceutical composition, a quasi-drug composition, or a food and drink composition.
6. A pharmaceutical composition, a quasi-drug composition, or a food and drink composition, comprising the composition for increasing Akkermansia bacteria according to any one of claims 1 to 4.
Citation Information
Patent Citations
Interleukin-23 production promoting composition and interleukin-23 production promoting method
WO2018151245A1
Wort fermentation product and use
JP2010155790A
JP236-239,2003
Anti-stress agent
WO2014132982A1
Serotonin deficiency amelioration agent for after stress-load release
WO2017047777A1
